Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
HOWL
Werewolf Therapeutics, Inc.
Platform-focused immune-modulating therapies and immuno-oncology programs fit Immunology Therapeutics.
|
$58.78M |
$1.30
-0.38%
|
|
GUTS
Fractyl Health, Inc. Common Stock
Revita DMR System is a medical device used in outpatient endoscopic/metabolic procedures, representing a direct product Fractyl Health develops and sells.
|
$58.28M |
$1.19
|
|
IPA
ImmunoPrecise Antibodies Ltd.
Core antibody discovery platform offering de novo antibody design and epitope mapping via LENSai/HYFT.
|
$57.82M |
N/A
|
|
NEPH
Nephros, Inc.
FDA-cleared medical devices (infection-control filters) used in hospitals and dialysis centers.
|
$56.92M |
$5.36
-6.05%
|
|
ICCC
ImmuCell Corporation
The company develops immunology-based therapeutics for animal health, including passive immunity and antimicrobial approaches used in calves and dairy cows.
|
$56.12M |
$6.09
-2.39%
|
|
ETST
Earth Science Tech, Inc.
ETST's core pharmaceutical operations include compounding pharmacies (RxCompound, Mister Meds) providing outsourced drug manufacturing services.
|
$55.82M |
$0.24
|
|
EQ
Equillium, Inc.
Equillium's pipeline focuses on immunology/inflammatory diseases, aligning with Immunology Therapeutics.
|
$55.36M |
$1.53
+8.51%
|
|
GANX
Gain Therapeutics, Inc.
GT-02287 is a small-molecule therapeutic candidate, aligning with the major product category of oral small-molecule therapeutics.
|
$54.39M |
$1.83
-6.63%
|
|
COEP
Coeptis Therapeutics, Inc.
GEAR Cell Therapy Platform is a core cell therapy biotech asset.
|
$54.22M |
$14.76
-3.02%
|
|
TELA
TELA Bio, Inc.
TELA Bio manufactures OviTex Reinforced Tissue Matrix, a medical device/biomaterial used in soft tissue reconstruction, aligning with Medical Devices & Biometrics.
|
$54.19M |
$1.36
-0.73%
|
|
CUE
Cue Biopharma, Inc.
CUE Biopharma is developing oncology-focused immunotherapies and cancer programs, aligning with Biotech - Oncology.
|
$54.06M |
$0.71
-0.92%
|
|
KRON
Kronos Bio, Inc.
Kronos Bio's core activity is oncology-focused biotechnology with a pipeline of small-molecule oncology agents, fitting Biotech - Oncology.
|
$53.65M |
$0.88
|
|
INKT
MiNK Therapeutics, Inc.
MiNK's lead product agenT-797 and pipeline comprise allogeneic, off-the-shelf iNKT cell therapies, a direct Cell Therapy business.
|
$53.61M |
$14.05
+4.46%
|
|
UNCY
Unicycive Therapeutics, Inc.
Lead programs Oxylanthanum Carbonate (OLC) and UNI-494 are oral small-molecule therapeutics targeting kidney disease and hyperphosphatemia/acute kidney injury.
|
$53.56M |
$4.45
+0.11%
|
|
OSTX
OS Therapies Incorporated
OSTX's lead therapy OST-HER2 is a cancer immunotherapy targeting oncology indications.
|
$52.54M |
$1.84
-1.60%
|
|
KPTI
Karyopharm Therapeutics Inc.
Karyopharm's core business is oncology-focused biotechnology/pharmaceuticals, including the approved cancer therapy XPOVIO (selinexor) and an oncology pipeline.
|
$52.44M |
$6.01
+3.62%
|
|
SNTI
Senti Biosciences, Inc.
Directly develops cancer therapies and immuno-oncology agents, notably SENTI-202 CAR-NK therapies targeting AML.
|
$52.16M |
$1.98
-1.25%
|
|
IPSC
Century Therapeutics, Inc.
Directly develops iPSC-derived cell therapies (CAR-iT, CAR-iNK, Allo-Evasion-enabled products) and related platforms.
|
$51.70M |
$0.60
+2.85%
|
|
PSTV
Plus Therapeutics, Inc.
Core product: radiopharmaceutical therapy using Rhenium-186 nanoliposomes for CNS cancers.
|
$51.39M |
$0.51
-6.65%
|
|
ANL
Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye is a clinical-stage biotechnology company focused on oncology therapies, establishing Biotech - Oncology as its core domain.
|
$51.24M |
$1.52
+6.29%
|
|
MDAI
Spectral AI, Inc.
DeepView is a diagnostic imaging device used to detect and manage wounds, fitting Diagnostic Equipment.
|
$50.98M |
$1.99
+0.51%
|
|
SRTS
Sensus Healthcare, Inc.
Sensus manufactures medical devices and biometric sensing technologies, including SRT therapy systems and related imaging components.
|
$50.98M |
$3.09
-0.32%
|
|
AIRG
Airgain, Inc.
AT-Flight asset tracker and its healthcare usage aligns Airgain with Medical Devices & Biometrics as a healthcare-oriented device offering.
|
$49.77M |
$4.20
-2.33%
|
|
CBUS
Cibus, Inc.
Reported contract research revenue indicates direct R&D services provided to clients alongside platform licensing.
|
$49.69M |
$1.45
-9.69%
|
|
ABVC
ABVC BioPharma, Inc.
ABVC's pipeline includes oncology therapeutics derived from plant compounds and cancer-focused programs.
|
$49.65M |
$2.96
+0.17%
|
|
BMEA
Biomea Fusion, Inc.
Direct product category: Biomea Fusion is developing oral small molecule therapeutics, including icovamenib and BMF-650.
|
$49.60M |
$1.30
-4.04%
|
|
BLGO
BioLargo, Inc.
Clyra Medical infection control products classify BioLargo under Medical Devices & Biometrics.
|
$49.44M |
$0.16
|
|
NRXP
NRx Pharmaceuticals, Inc.
NRx's pipeline centers on neuropsychiatric drug development (NRX-100, NRX-101) targeting suicidal depression and bipolar depression.
|
$49.27M |
$2.85
-8.06%
|
|
CTSO
Cytosorbents Corporation
CytoSorbents' core offering is the CytoSorb blood purification device used in ICU and cardiac surgery to remove inflammatory mediators and toxins.
|
$48.87M |
$0.75
-4.43%
|
|
BRNS
Barinthus Biotherapeutics plc
Company is pivoting to immunology/inflammation therapeutics and is advancing T‑cell immunotherapies (SNAP-TI), with VTP-1000 for celiac disease as lead candidate.
|
$48.00M |
$1.24
+4.20%
|
|
INMB
INmune Bio, Inc.
Directly represents INmune Bio's Alzheimer's disease therapeutics focus under the XPro DN-TNF program.
|
$47.85M |
$1.80
-1.37%
|
|
RFL
Rafael Holdings, Inc.
NPC1 rare-disease program (Trappsol Cyclo) places Rafael Holdings in the Biotech - Rare Diseases category.
|
$47.37M |
$1.34
-0.74%
|
Showing page 28 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
